Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

hospira benelux bv-srl - aciclovir sodium - eq. aciclovir 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - aciclovir sodium - aciclovir

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals sa-nv - aciclovir sodium - eq. aciclovir 250 mg - powder for solution for injection - 250 mg - aciclovir sodium - aciclovir

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - valaciclovir hydrochloride, quantity: 556.275 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores) for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see section 4.4 special warnings and precautions for use). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - valaciclovir hydrochloride monohydrate 1223.4mg equivalent to valaciclovir base 1000 mg - film coated tablet - 1000 mg - active: valaciclovir hydrochloride monohydrate 1223.4mg equivalent to valaciclovir base 1000 mg excipient: magnesium stearate microcrystalline cellulose opadry white y-5-7068 povidone - valaciclovir actavis is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - valaciclovir hydrochloride monohydrate 305.85mg equivalent to valaciclovir base 250 mg - film coated tablet - 250 mg - active: valaciclovir hydrochloride monohydrate 305.85mg equivalent to valaciclovir base 250 mg excipient: magnesium stearate microcrystalline cellulose opadry white y-5-7068 povidone - valaciclovir actavis is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - valaciclovir hydrochloride monohydrate 611.7mg equivalent to valaciclovir base 500 mg - film coated tablet - 500 mg - active: valaciclovir hydrochloride monohydrate 611.7mg equivalent to valaciclovir base 500 mg excipient: magnesium stearate microcrystalline cellulose opadry white y-5-7068 povidone - valaciclovir actavis is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - aciclovir sodium 628.8mg equivalent to aciclovir 500 mg - powder for infusion - 500 mg - active: aciclovir sodium 628.8mg equivalent to aciclovir 500 mg - aciclovir is indicated for the treatment of herpes simplex infections. aciclovir is indicated for the prophylaxis of herpes simplex infections in immune-compromised patients. aciclovir is indicated for the treatment of varicella zoster infections. aciclovir is indicated for the treatment of herpes simplex infections in the neonate. aciclovir infusion formulations are indicated for the prophylaxis of cmv infection in bone marrow transplant recipients. it has been shown that high dose intravenous aciclovir reduces the incidence and delays the onset of cmv infection. when high dose intravenous aciclovir is followed by 6 months treatment with high dose oral aciclovir (see prescribing information for oral aciclovir) mortality and the incidence of viraemia are also reduced.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - aciclovir - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - aciclovir - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sterwin medicines - aciclovir - oral tablet - 200mg